SRC (Ab-529) Antibody

What is the SRC (Ab-529) Antibody and what epitope does it recognize?

SRC (Ab-529) Antibody is a rabbit polyclonal antibody that specifically recognizes the peptide sequence around amino acids 527-531 (P-Q-Y-Q-P) of human Src protein. This antibody detects endogenous levels of total Src protein and is not phospho-specific, making it useful for measuring total Src expression regardless of its phosphorylation state . The antibody has been generated by immunizing rabbits with a synthetic peptide derived from this region conjugated to KLH (Keyhole Limpet Hemocyanin) and purified using affinity chromatography with the epitope-specific peptide .

What species reactivity has been confirmed for the SRC (Ab-529) Antibody?

SRC (Ab-529) Antibody has been validated for reactivity with Src protein from multiple species. According to multiple product datasheets, the antibody effectively recognizes human, mouse, and rat Src proteins . This cross-species reactivity makes it a valuable tool for comparative studies across different experimental models. When designing experiments using new cell lines or tissue samples, researchers should consider performing preliminary validation experiments to confirm reactivity in their specific experimental system.

What are the recommended applications and dilutions for SRC (Ab-529) Antibody?

The SRC (Ab-529) Antibody has been validated for multiple experimental applications with the following recommended dilutions:

These recommendations serve as starting points, and optimal dilutions may vary depending on the specific experimental conditions, sample type, and detection method used . It is advisable to perform titration experiments when using this antibody in a new application or with a new sample type.

How should the SRC (Ab-529) Antibody be stored to maintain optimal activity?

According to product information, the SRC (Ab-529) Antibody is supplied at a concentration of 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150 mM NaCl, 0.02% sodium azide, and 50% glycerol . For short-term storage, the antibody can be kept at 4°C, while for long-term preservation, storage at -20°C or -80°C is recommended . To maintain antibody integrity, repeated freeze-thaw cycles should be avoided by preparing small working aliquots before freezing. Proper storage practices will help ensure consistent experimental results over time.

How can I distinguish between active and inactive forms of Src when using SRC (Ab-529) Antibody versus phospho-specific antibodies?

Understanding Src activation status requires strategic use of different antibodies. While SRC (Ab-529) Antibody detects total Src protein regardless of phosphorylation status, researchers interested in Src activity should employ phospho-specific antibodies targeting key regulatory sites. Src activity is primarily regulated by phosphorylation at two critical tyrosine residues:

• Phosphorylation at Y418 (activation loop) increases kinase activity

• Phosphorylation at Y529 (C-terminal) inhibits kinase activity

For comprehensive analysis, researchers should use a combination of:

• SRC (Ab-529) Antibody for total Src protein levels

• Anti-Src (pY418) antibody to detect active Src

• Anti-Src (pY529) antibody to detect inactive Src

The ratio of phosphorylated Y418 to Y529 provides insight into the proportion of active versus inactive Src in your experimental system . As demonstrated in studies of cell adhesion signaling, "activity status of SFK was assessed by immunoblotting with anti-Src (pY418) and anti-Src (pY529) antibodies that recognize an autophosphorylated tyrosine of multiple SFK members and a phosphorylated tyrosine at the negative regulatory site, respectively" .

What are the optimal experimental conditions for studying Src activation dynamics in cell adhesion models?

When investigating Src activation dynamics during cell adhesion events, temporal resolution is critical. Research has shown that Src family kinase (SFK) activation occurs within minutes of cell attachment to extracellular matrix proteins like fibronectin and precedes full focal adhesion kinase (FAK) activation .

For optimal experimental design:

• Time course analysis: Sample collection at multiple time points (0, 5, 10, 15, 30, 60 minutes) after cell plating is crucial to capture the transient activation peak.

• Proper controls: Include both suspended cells (0 min) and fully adhered cells (60+ min) to establish baseline and endpoint Src activity.

• Subcellular fractionation: Isolate lipid raft fractions to analyze compartmentalized Src signaling, as "In wild-type cells, activation of SFK was detected within 10 min after plating... Simultaneously, increases in tyrosine phosphorylation of Cbp and recruitment of Csk to the raft fraction were observed" .

• Antibody panel: Use SRC (Ab-529) Antibody alongside phospho-specific antibodies (pY418 and pY529) to comprehensively monitor activation status changes throughout the adhesion process.

• Downstream target analysis: Include analysis of FAK phosphorylation (particularly at Y861) to correlate Src activation with downstream signaling events .

This experimental approach will enable detection of the biphasic regulation of Src during cell adhesion, characterized by initial activation followed by Csk-mediated downregulation.

How can I effectively use SRC (Ab-529) Antibody in conjunction with dominant-active Src mutants in experimental systems?

When designing experiments involving dominant-active (DA) Src mutants alongside antibody detection, careful consideration of epitope recognition is essential. The Y529F mutation, which prevents inhibitory phosphorylation and generates constitutively active Src, falls within the epitope recognition region of SRC (Ab-529) Antibody (aa 527-531) .

Recommended experimental approach:

• Epitope verification: Confirm that the Y529F mutation does not interfere with SRC (Ab-529) Antibody binding through side-by-side comparison with other Src antibodies targeting different epitopes.

• Expression system design: Generate cells expressing HA-tagged DA-Src to enable detection with anti-HA antibodies as an alternative verification method, as demonstrated in research where "HA-tagged DA c-Src HNSCC cells were also generated separately by transfection with a dominant-active Src construct engineered to contain an HA tag" .

• Functional validation: Confirm DA-Src activity through:

  • Increased auto-phosphorylation at Y418

  • Enhanced phosphorylation of known Src substrates (FAK Y861, p130Cas)

  • Elevated invasive potential in Matrigel invasion assays

• Signal quantification: Use SRC (Ab-529) Antibody to quantify total Src levels relative to phospho-Y418 levels to determine the proportion of active Src in your experimental system.

This strategic approach enables reliable detection and functional characterization of DA-Src in experimental systems, facilitating research on Src-dependent cellular processes.

What technical considerations should be addressed when using SRC (Ab-529) Antibody in multiplexed immunoassays?

Multiplexed detection systems require careful optimization to prevent cross-reactivity and ensure specific signal detection. When incorporating SRC (Ab-529) Antibody into multiplex panels:

• Antibody compatibility screening: Test SRC (Ab-529) Antibody with other antibodies in your panel using identical samples processed with single antibody vs. multiplexed conditions to identify potential interference.

• Species-matched secondary antibodies: Since SRC (Ab-529) is rabbit-derived, ensure secondary antibodies for other rabbit primaries use different detection systems (e.g., different fluorophores or chromogens) to prevent cross-reactivity.

• Signal optimization: For immunofluorescence applications:

  • Use Tyramide Signal Amplification (TSA) for weak signals

  • Consider sequential rather than simultaneous antibody incubation when detecting multiple phospho-epitopes

  • Include phosphatase inhibitors in all buffers when detecting phospho-epitopes alongside total Src

• Validation controls:

  • Include Src-knockout or siRNA-silenced samples as negative controls

  • Use samples with known Src expression levels as positive controls

  • Include isotype control antibodies to identify non-specific binding

These methodological considerations will help ensure specific, reproducible detection of Src protein in complex multiplexed experimental systems.

What are common issues when working with SRC (Ab-529) Antibody in Western blotting, and how can they be resolved?

Western blotting with SRC (Ab-529) Antibody may present several technical challenges that can be systematically addressed:

For optimal results with SRC (Ab-529) Antibody in Western blotting, lysate preparation is critical. Based on research protocols, cells should be lysed in buffer containing phosphatase inhibitors to preserve Src phosphorylation status. When studying Src activation dynamics, a 2-hour treatment with inhibitors like AZD0530 prior to cell lysis can help establish baseline activity levels .

How should I design experiments to investigate Src activity in relation to cell invasion and migration?

When designing experiments to study Src's role in invasion and migration processes, a multi-faceted approach incorporating both molecular and functional readouts is recommended:

• Baseline characterization:

  • Determine endogenous Src expression and activation status in your cell model using SRC (Ab-529) Antibody (total Src) and phospho-specific antibodies (Y418, Y529)

  • Assess expression of key Src regulators (Csk, Cbp) and substrates (FAK, p130Cas)

• Functional modulation strategies:

  • Pharmacological: Treat cells with Src inhibitors (e.g., AZD0530) at IC₅₀ concentrations determined through dose-response curves

  • Genetic: Generate stable cell lines expressing dominant-active Src (Y529F) or use siRNA knockdown approaches

  • Combination approaches: Combine Src inhibition with inhibitors of related pathways (e.g., EGFR inhibition with gefitinib)

• Functional assays:

  • Matrigel invasion assay: Plate 1×10⁴ cells/well in serum-free media in upper chamber with treatments, 10% FBS in lower chamber, assess invasion after 48 hours

  • Wound healing assay: Create standardized wounds in confluent monolayers, measure closure rate over 24-48 hours under different treatment conditions

  • Proliferation assay: Plate 3×10⁴ cells/well, treat with inhibitors at IC₅₀ values, count viable cells at multiple timepoints

• Molecular correlation:

  • Collect parallel samples for Western blot analysis at key timepoints during functional assays

  • Correlate changes in Src activation status with functional outcomes

This comprehensive approach will enable robust assessment of Src's role in invasion and migration while providing mechanistic insights into the molecular processes involved.

What considerations are important when using SRC (Ab-529) Antibody alongside phospho-specific antibodies in studies of Src regulation?

When designing experiments to investigate Src regulation using both total and phospho-specific antibodies, several critical factors must be addressed:

Careful attention to these methodological details will ensure reliable interpretation of results when investigating the complex regulatory mechanisms controlling Src activity.

How can I distinguish between different Src family kinases (SFKs) when using SRC (Ab-529) Antibody in complex cellular systems?

Distinguishing between Src family kinases presents a significant challenge due to high sequence homology. When using SRC (Ab-529) Antibody in systems expressing multiple SFKs, implement a strategic approach:

• Sequential immunodepletion:

  • Perform sequential immunoprecipitations with SFK member-specific antibodies

  • Analyze the depleted lysates with SRC (Ab-529) Antibody to determine the proportion of signal attributable to each family member

• Subcellular localization analysis:

  • Different SFKs show distinct subcellular localization patterns that can aid identification

  • Research has shown that "Fyn was constitutively localized in lipid rafts during the cell adhesion process. In contrast, although Src was found in lipid rafts of the cells in suspension, it disappeared from there at early stages of cell adhesion"

  • Perform subcellular fractionation (membrane, cytosolic, nuclear, lipid raft) followed by immunoblotting

• Genetic approaches:

  • Utilize siRNA-mediated knockdown of specific SFK members

  • Generate knockout/knockdown cell lines for individual SFKs using CRISPR-Cas9

  • Compare SRC (Ab-529) Antibody signal before and after genetic manipulation

• Family member-specific functions:

  • Design experiments that leverage known functional differences between SFKs

  • For example, "only Fyn is tightly associated with Cbp phosphorylation, supporting its preferential role in Cbp phosphorylation"

This multifaceted approach enables researchers to delineate the specific contributions of individual SFK members in complex experimental systems.

What experimental approaches can uncover the dynamic interplay between Src and its regulatory partners during cell signaling events?

Investigating the dynamic relationship between Src and its regulatory partners requires sophisticated experimental approaches that capture both spatial and temporal aspects of these interactions:

• Proximity ligation assays (PLA):

  • Utilize SRC (Ab-529) Antibody together with antibodies against regulatory proteins (Csk, Cbp/PAG)

  • PLA generates fluorescent signals only when proteins are within 40nm, enabling visualization of protein interactions in situ

  • Quantify interaction dynamics at different timepoints following stimulus

• Co-immunoprecipitation with phosphorylation state analysis:

  • Immunoprecipitate Src using SRC (Ab-529) Antibody at different timepoints after stimulation

  • Analyze co-precipitating proteins (Csk, Cbp) by immunoblotting

  • Simultaneously assess phosphorylation status of Src (pY418, pY529) and binding partners

  • Research has shown that "upon cell adhesion onto fibronectin, Cbp becomes transiently phosphorylated (consistent with SFK activation) and recruits Csk to lipid rafts"

• Lipid raft isolation with differential detergent extraction:

  • Isolate detergent-resistant membrane fractions at multiple timepoints

  • Analyze Src localization and activation status using SRC (Ab-529) Antibody and phospho-specific antibodies

  • Simultaneously track regulatory partners (Csk, Cbp) in these fractions

• Live-cell FRET imaging:

  • Generate fluorescent protein-tagged Src and regulatory partners

  • Measure protein-protein interactions in real-time following stimulation

  • Correlate with functional outcomes using parallel biochemical analyses with SRC (Ab-529) Antibody

These approaches provide complementary insights into the spatiotemporal regulation of Src during complex signaling events, revealing "that Cbp could serve as a sensor of SFK activity in early stages of cell adhesion signaling, and that Csk-mediated down-regulation of SFK is essential" .

How can I optimize immunohistochemical protocols using SRC (Ab-529) Antibody for analysis of clinical specimens?

Optimizing immunohistochemistry (IHC) protocols for clinical specimens requires systematic evaluation of multiple parameters to ensure specific, reproducible staining with SRC (Ab-529) Antibody:

• Antigen retrieval optimization:

  • Test multiple methods (heat-induced epitope retrieval in citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Evaluate different retrieval durations (10, 20, 30 minutes)

  • For formalin-fixed tissues, more aggressive retrieval may be necessary to expose the epitope recognized by SRC (Ab-529) Antibody

• Antibody titration matrix:

  • Test concentration range from 1:50 to 1:200 based on recommended dilutions

  • Vary incubation conditions (4°C overnight vs. room temperature for 1-2 hours)

  • Include positive control tissues with known Src expression (platelets, neurons, macrophages) as "these tissues express 5-fold to 200-fold higher levels than most other tissues"

• Detection system selection:

  • Compare avidin-biotin complex (ABC) vs. polymer-based detection systems

  • Evaluate signal-to-noise ratio with DAB vs. AEC chromogens

  • Consider tyramide signal amplification for low abundance targets

• Validation with complementary approaches:

  • Confirm staining pattern with phospho-specific Src antibodies on serial sections

  • Correlate IHC results with Western blot analysis of matched frozen specimens

  • Include isotype controls and Src-low tissues as negative controls

• Scoring system development:

  • Establish quantitative scoring system (H-score, Allred score) for Src expression

  • Document subcellular localization patterns (membrane, cytoplasmic, nuclear)

  • Consider digital image analysis for objective quantification

These methodical optimization steps will enable reliable detection of Src in clinical specimens, facilitating translational research on Src's role in human disease.

What considerations are important when designing experiments to study Src ubiquitination and degradation pathways?

Investigating Src ubiquitination and degradation requires specialized experimental approaches that preserve these transient post-translational modifications while enabling their specific detection:

• Lysate preparation adaptations:

  • Add deubiquitinase inhibitors (N-ethylmaleimide, PR-619) to standard lysis buffers

  • Include proteasome inhibitors (MG132, bortezomib) in treatment conditions to accumulate ubiquitinated species

  • Use denaturing lysis conditions (1% SDS with boiling) followed by dilution for immunoprecipitation to disrupt protein-protein interactions

• Experimental design for degradation kinetics:

  • Implement cycloheximide chase assays to block new protein synthesis

  • Collect samples at multiple timepoints (0, 2, 4, 8, 16, 24 hours)

  • Use SRC (Ab-529) Antibody to monitor total Src levels over time

  • Research has shown that "in the Csk-deficient cells, Src protein was markedly down-regulated potentially through ubiquitination"

• Ubiquitination detection strategies:

  • Immunoprecipitate Src using SRC (Ab-529) Antibody, then probe for ubiquitin

  • Alternatively, immunoprecipitate ubiquitinated proteins, then probe for Src

  • Use antibodies specific for different ubiquitin linkages (K48, K63) to distinguish degradative vs. regulatory ubiquitination

• E3 ligase identification approaches:

  • Investigate known Src E3 ligases (CBLC) through co-immunoprecipitation

  • Implement siRNA screening of candidate E3 ligases and monitor effects on Src stability

  • The literature indicates "Ubiquitination mediated by CBLC requires SRC autophosphorylation at Tyr-419 and may lead to lysosomal degradation"

• Degradation pathway determination:

  • Compare effects of proteasome inhibitors vs. lysosome inhibitors (chloroquine, bafilomycin A1)

  • Monitor Src localization to lysosomes vs. proteasomes through co-localization studies

  • Assess the impact of phosphorylation status on degradation pathway routing

These methodological considerations will enable robust investigation of the complex processes regulating Src protein stability and turnover in various experimental systems.

How might recent advances in proximity labeling techniques be integrated with SRC (Ab-529) Antibody to map the dynamic Src interactome?

Integrating proximity labeling approaches with traditional antibody-based detection offers powerful new opportunities to map the Src interactome with unprecedented detail. Future research directions could include:

• BioID or TurboID fusion protein approaches:

  • Generate Src-BioID fusion constructs to biotinylate proteins in close proximity to Src

  • Validate fusion protein localization and activity using SRC (Ab-529) Antibody

  • Purify biotinylated proteins for mass spectrometry analysis

  • Compare interactomes under different conditions (serum-starved vs. stimulated)

• Split-TurboID complementation systems:

  • Develop split-TurboID constructs for Src and candidate interacting proteins

  • Proximity-dependent biotinylation occurs only when proteins interact

  • Validate interactions by standard co-immunoprecipitation with SRC (Ab-529) Antibody

  • This approach could help identify transient interactions during signaling events

• APEX2-based spatial proteomics:

  • Generate Src-APEX2 fusions to map proteins within nanometer-scale proximity

  • Include subcellular targeting sequences to focus on specific compartments (lipid rafts, focal adhesions)

  • Combine with phosphoproteomics to identify substrates and regulatory partners

  • Validate key interactions using SRC (Ab-529) Antibody in traditional biochemical assays

• Temporal interactome mapping:

  • Implement pulsed labeling approaches to capture dynamic changes in the Src interactome

  • Correlate with activation status determined by phospho-specific antibodies

  • This approach could reveal how "Phosphorylation of an activation loop tyrosine activates the enzyme; phosphorylation of a tyrosine in the C-terminus by Csk inhibits the enzyme" impacts protein-protein interactions

These emerging technologies, when combined with established antibody-based detection methods, will provide unprecedented insights into the spatial and temporal organization of Src signaling complexes.

What is the potential for using SRC (Ab-529) Antibody in single-cell analysis techniques to understand Src expression heterogeneity in complex tissues?

Single-cell analysis technologies offer exciting opportunities to understand heterogeneity in Src expression and activation within complex tissues. Future applications combining SRC (Ab-529) Antibody with single-cell techniques may include:

• Single-cell mass cytometry (CyTOF):

  • Develop metal-conjugated SRC (Ab-529) Antibody for CyTOF analysis

  • Combine with phospho-specific antibodies and lineage markers

  • Analyze heterogeneity in total Src expression and activation state across different cell populations

  • This approach could reveal how the observation that "Platelets, neurons and osteoclasts express 5-fold to 200-fold higher levels than most other tissues" manifests at the single-cell level

• Imaging mass cytometry:

  • Apply metal-labeled SRC (Ab-529) Antibody to tissue sections

  • Maintain spatial context while quantifying protein expression at single-cell resolution

  • Correlate Src expression with tissue architecture and microenvironmental features

• Single-cell Western blotting:

  • Analyze individual cells for total Src and phospho-Src levels

  • Quantify cell-to-cell variability in Src expression and activation

  • Correlate with functional cellular states or responses to therapy

• Spatial transcriptomics integration:

  • Combine SRC (Ab-529) Antibody immunofluorescence with spatial transcriptomics

  • Correlate protein expression with transcriptional programs at single-cell resolution

  • Identify regulatory mechanisms controlling heterogeneous Src expression

These emerging technologies will enable researchers to move beyond population averages to understand how heterogeneity in Src expression and activation contributes to cellular function in complex tissues and disease states.

How can computational modeling be integrated with experimental data using SRC (Ab-529) Antibody to predict Src activation dynamics?

Integrating computational modeling with experimental data represents a powerful approach to understanding the complex dynamics of Src regulation. Future research directions may include:

• Quantitative Western blot data integration:

  • Use SRC (Ab-529) Antibody alongside phospho-specific antibodies to generate quantitative time-course data

  • Develop ordinary differential equation (ODE) models of Src activation/inactivation kinetics

  • Calibrate models using experimental data from multiple conditions

  • Test model predictions with targeted experiments

• Agent-based modeling of spatial Src regulation:

  • Incorporate spatial information from immunofluorescence studies using SRC (Ab-529) Antibody

  • Model membrane microdomains and protein diffusion processes

  • Simulate how "Src was found in lipid rafts of the cells in suspension, it disappeared from there at early stages of cell adhesion and then relocated when cell spreading was complete"

  • Test predictions regarding spatial segregation of activation/inactivation processes

• Multi-scale modeling frameworks:

  • Link molecular-scale models of Src conformational changes to cellular-scale models of downstream signaling

  • Integrate experimental data from multiple scales (protein biochemistry to cell behavior)

  • Predict emergent properties of the system under various perturbations

• Machine learning approaches:

  • Develop predictive models of Src activation based on multiplexed antibody data

  • Identify patterns and relationships not apparent through traditional analysis

  • Generate hypotheses regarding complex regulatory mechanisms for experimental testing